StoneX Group’s ARS Pharmaceuticals SPRY Stock Holding History

StoneX Group’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-11,280	Closed	-$42.6K	–	445
2023 Q3	$42.6K	Buy	+11,280	New	+$74K	0.02%	329

Other funds holding SPRY

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

CST

Charles Schwab Trust Henderson, Nevada $1.79B AUM 17.47% 1-Year Est. Return

KPF

K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

StoneX Group's SPRY Position: Q4 2023 in Review

StoneX Group sold out of ARS Pharmaceuticals (SPRY) in Q4 2023, closing a stake of 11,280 shares — an estimated $42.6K sold.

StoneX Group first reported a position in SPRY in Q3 2023 and held it in 1 quarter. The position peaked at $42.6K in Q3 2023. 100 funds tracked by Wall St. Rank hold SPRY as of Q4 2023.

StoneX Group reported no remaining ARS Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
StoneX Group sold 11,280 ARS Pharmaceuticals shares in Q4 2023, an estimated $42.6K.
StoneX Group first reported a position in ARS Pharmaceuticals in Q3 2023 and held it in 1 quarter.
StoneX Group's ARS Pharmaceuticals position peaked at $42.6K in Q3 2023.
100 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q4 2023.

Based on StoneX Group's 13F filing for Q4 2023, filed 12 Feb 2024.